DF2156A ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 3 |
162. 類天疱瘡（後天性表皮水疱症を含む。）
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01571895 (ClinicalTrials.gov) | February 20, 2012 | 4/4/2012 | Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid | A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. | Bullous Pemphigoid | Drug: DF2156A | Dompé Farmaceutici S.p.A | NULL | Terminated | 18 Years | N/A | All | 4 | Phase 2 | Germany;Italy |
| 2 | EUCTR2011-000756-42-IT (EUCTR) | 30/06/2011 | 20/03/2012 | pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: NA Product Code: DF2156A INN or Proposed INN: ladarixin | DOMPE' s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy | ||
| 3 | EUCTR2011-000756-42-DE (EUCTR) | 08/06/2011 | Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: not applicable Product Code: DF2156A INN or Proposed INN: ladarixin | Dompé s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy |